Navigation Links
Innovative smallpox vaccine research study to be conducted at Case Medical Center

University Hospitals Case Medical Center (UHCMC) and Case Western Reserve University School of Medicine are part of a nationwide research study to determine the safety and effectiveness of a new smallpox vaccine geared toward adults ages 18 to 34 who have never been vaccinated against the disease. The study is the first of its type in Northeast Ohio.

The current FDA-approved vaccine, Dryvax®, is not recommended for use on everyone because of the potential for serious side effects in certain individuals. “For example, the current vaccine cannot be used in immune-compromised individuals, such as patients with HIV or individuals with certain skin conditions such as eczema,” says Robert A. Salata, M.D., chief of the Division of Infectious Diseases at Case Western Reserve University School of Medicine and UHCMC.

The new vaccine, IMVAMUNE®, is different from Dryvax® in that it contains a more weakened form of the live-virus within the vaccine.

“Because the vaccine is weakened, the side effects should be minimized enough to give the vaccine to all individuals, even those whose immune systems are suppressed,” says Dr. Salata. “Our hope is that the new vaccine will be a safer alternative to the current vaccine.”

UHCMC and the School of Medicine will act as a subunit of St. Louis University’s Center for Vaccine Development, which is one of seven national testing sites known as Vaccine and Treatment Evaluation Units (VTEUs), designated by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The research study, which is actively recruiting and begins here June 15, will follow 215 volunteers nationwide over a two-year period. Volunteers must be in general good health and must not have previously been vaccinated against smallpox.

Smallpox is a contagious and sometimes fatal infectious disease characterized by raised bumps that appear on the face and body of an infected person. There is no specific treatment for smallpox disease, and the only prevention is vaccination. The World Health Organization declared the disease eradicated in 1980 with the success of a worldwide vaccination program. Routine vaccination against smallpox among the general public was ceased in 1972 because it was no longer necessary for prevention. However, recent threats of bioterrorism after 9/11 have spurred the development of a new safer vaccine that can be given to immune-compromised individuals.
'"/>

Source:Case Western Reserve University


Related biology news :

1. Innovative collaboration brings Arctic science into the classroom
2. Innovative coating could give medical implants a longer life
3. Innovative method for creating a human cytomegalovirus vaccine outlined
4. Innovative movies show real-time immune-cell activity within tumors
5. Stopping smallpox in its tracks: A new anti-viral approach
6. Secret of smallpoxs success may lead to bioterror cure
7. LIAI scientists make major finding on potential smallpox treatment
8. Researchers develop new testing methods for potential monkeypox or smallpox outbreak
9. Serious adverse reactions to smallpox vaccine appear to be limited
10. Mice studies illustrate potential of chimp/human antibodies to protect against smallpox
11. Defective immune system response to smallpox vaccine detailed in new study

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/20/2016)... Dec. 20, 2016 The rising popularity ... and leasing is stoking significant interest in keyless ... technology, Bluetooth low energy (BLE), biometrics and near-field ... next wave of wireless technologies in the automotive ... to advanced access systems opens the market to ...
(Date:12/19/2016)... TORONTO , 19 de diciembre de 2016  Mosaic Biomedicals ... el desarrollo acelerado de MSC-1, un anticuerpo humanizado que se espera ... en 2017, con múltiples sitios previstos a lo largo de Europa ... MSC-1 ... factor inhibidor de leucemia (LIF), una citoquina pleiotrópica que se sobreexpresa ...
(Date:12/16/2016)... DUBLIN , Dec 16, 2016 Research ... Access System Market - Global Forecast to 2021" report to ... ... projected to grow at a CAGR of 14.06% from 2016 to ... 2016, and is projected to reach 854.8 Million by 2021. The ...
Breaking Biology News(10 mins):
(Date:1/17/2017)... -- On January 10 at the Medtech Showcase held in ... in San Francisco , ProclaRx CEO, ... pharmaceutical leaders and public and private investors about the ... destroy biofilms.  Biofilms are a physical ... body,s immune system from eradicating chronic infections. Infections with biofilms ...
(Date:1/14/2017)... ... January 14, 2017 , ... Seattle-based Phase Genomics has announced ... to researchers around the globe. Long considered a “holy grail” in biological ... range of scientific questions. The announcement was made today at the Plant ...
(Date:1/13/2017)... ... January 13, 2017 , ... FireflySci has been busy rolling ... its diverse customer base. The latest entry in this field is a series ... and Bio-Rad. FireflySci is introducing three distinct varieties including a 10x1mm, 10x2 and ...
(Date:1/12/2017)... NE (PRWEB) , ... January 12, 2017 , ... ... hiring of Stephen Beck, who will work in the company’s Lincoln office as a ... chemical processes to design control systems for customers in the life science manufacturing and ...
Breaking Biology Technology: